Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily

oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]

#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment

How to watch one of the year's best meteor showers, the Geminids

3 months / go

Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025

3 months / oncodaily

Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 2 months

FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers

Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Anastasia Conti: Excited to Speak at CRISPRMED26 in Copenhagen

2 months / oncodaily

Western genetic medicine makers turn to Chinese investigator-initiated trials

2 months / endpoints / Ryan Cross

FDA Flexibility Leads to First Approved Gene Therapy for Rare Blood & Immune System Disorder

3 months / medcitynews / Frank Vinluan

FDA approves 1st gene therapy for Wiskott-Aldrich syndrome

3 months / beckershospitalreview / Ella Jeffries

Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 2 months

HEALTHCARE Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.

More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...

CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...

Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...

City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...